The FELIX study was conducted across 34 sites in Spain, the United Kingdom, and the United States in adults with relapsed or refractory CD19-positive B-cell ALL. Eligible patients were at least 18 ...

More than three-quarters of patients with B-cell acute lymphoblastic leukemia responded to Aucatzyl More than half went into remission, with many showing no residual cancer in their bodies TUESDAY, ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL ... and about 45%-60% of adults have long-term disease-free survival. Acute refers to the relatively ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

Opens in a new tab or window SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL ... of relapsed or refractory B-cell ALL in adult patients in Nov. 2024. Additional findings from ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

Tisagenlecleucel is also approved for use in children and young adults with acute lymphoblastic B-cell leukemia. The CAR-T-cell therapies targeting B-cell maturation antigen — ciltacabtagene ...